Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARTA: Vebreltinib in MET-altered Solid Tumors
NCT03175224Phase 2Recruiting
- Sponsor
- Apollomics, Inc.
- Start
- Sep 2017
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label trial of vebreltinib in non-small cell lung cancer (NSCLC), solid tumor and central nervous system tumor, sponsored by Apollomics, Inc. Primary endpoint: Objective Response Rate. Started Sep 2017; status: recruiting.
02
Drugs
vebreltinib
03
Conditions
non-small cell lung cancer (NSCLC)solid tumorcentral nervous system tumor
Beyond the preview
Go deeper on NCT03175224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03175224.